Abstract
Nucleic acid therapies have gained significant traction in recent years as a promising new approach to treating various genetic diseases. Such therapies employ synthetic, small molecules called antisense oligonucleotides (AOs) which are capable of modulating the transfer of genetic information from nucleic acid to protein through various mechanisms, including the augmentation of pre-mRNA splicing and downregulation of expression. Thus, AOs can prevent the incorporation of genetic mutations causing disease into final protein transcripts as well as reduce levels of mutant transcripts, potentially ameliorating disease phenotype. This process, also known as antisense therapy, has recently been the subject of several preclinical and clinical trials aimed at treating muscular dystrophies. Thanks to recent advancements in antisense drug chemistries, numerous studies have demonstrated the safety, tolerability, and efficacy of AOs administered to patients with Duchenne muscular dystrophy, the most common form of muscular dystrophy. In the wake of promising clinical trial data, it may well be that the first federally approved marketable antisense drug for treating muscular dystrophy could be on the horizon.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Helene C, Toulme JJ (1990) Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim Biophys Acta 1049(2):99–125
Lee J, Yokota T (2013) Antisense therapy in neurology. J Pers Med 3(3):144–176. doi:10.3390/jpm3030144#sthash.EzKjmG9w.dpuf
Touznik A, Lee JJ, Yokota T (2014) New developments in exon skipping and splice modulation therapies for neuromuscular diseases. Expert Opin Biol Ther 14(6):809–819. doi:10.1517/14712598.2014.896335
Spiegelman WG, Reichardt LF, Yaniv M, Heinemann SF, Kaiser AD, Eisen H (1972) Bidirectional transcription and the regulation of Phage lambda repressor synthesis. Proc Natl Acad Sci U S A 69(11):3156–3160
Green PJ, Pines O, Inouye M (1986) The role of antisense RNA in gene regulation. Annu Rev Biochem 55:569–597. doi:10.1146/annurev.bi.55.070186.003033
Itoh T, Tomizawa J (1980) Formation of an RNA primer for initiation of replication of ColE1 DNA by ribonuclease H. Proc Natl Acad Sci U S A 77(5):2450–2454
Simons RW, Kleckner N (1988) Biological regulation by antisense RNA in prokaryotes. Annu Rev Genet 22:567–600. doi:10.1146/annurev.ge.22.120188.003031
Tomizawa J, Itoh T, Selzer G, Som T (1981) Inhibition of ColE1 RNA primer formation by a plasmid-specified small RNA. Proc Natl Acad Sci U S A 78(3):1421–1425
Light J, Molin S (1983) Post-transcriptional control of expression of the repA gene of plasmid R1 mediated by a small RNA molecule. EMBO J 2(1):93–98
Mizuno T, Chou MY, Inouye M (1984) A unique mechanism regulating gene expression: translational inhibition by a complementary RNA transcript (microRNA). Proc Natl Acad Sci U S A 81(7):1966–1970
Simons RW, Kleckner N (1983) Translational control of IS10 transposition. Cell 34(2):683–691
Zamecnik PC, Stephenson ML (1978) Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci U S A 75(1):280–284
Izant JG, Weintraub H (1985) Constitutive and conditional suppression of exogenous and endogenous genes by anti-sense RNA. Science 229(4711):345–352
McGarry TJ, Lindquist S (1986) Inhibition of heat shock protein synthesis by heat-inducible antisense RNA. Proc Natl Acad Sci U S A 83(2):399–403
Yokota T, Takeda S, Lu QL, Partridge TA, Nakamura A, Hoffman EP (2009) A renaissance for antisense oligonucleotide drugs in neurology: exon skipping breaks new ground. Arch Neurol 66(1):32–38
Miller PS, Braiterman LT, Ts’o PO (1977) Effects of a trinucleotide ethyl phosphotriester, Gmp(Et)Gmp(Et)U, on mammalian cells in culture. Biochemistry 16(9):1988–1996
Bendifallah N, Rasmussen FW, Zachar V, Ebbesen P, Nielsen PE, Koppelhus U (2006) Evaluation of cell-penetrating peptides (CPPs) as vehicles for intracellular delivery of antisense peptide nucleic acid (PNA). Bioconjug Chem 17(3):750–758. doi:10.1021/bc050283q
Hoffman EP, Bronson A, Levin AA, Takeda S, Yokota T, Baudy AR, Connor EM (2011) Restoring dystrophin expression in Duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through. Am J Pathol 179(1):12–22. doi:10.1016/j.ajpath.2011.03.050
Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5(10):987–995. doi:10.1038/ni1112
Juliano R, Bauman J, Kang H, Ming X (2009) Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol Pharm 6(3):686–695. doi:10.1021/mp900093r
Lu QL, Yokota T, Takeda S, Garcia L, Muntoni F, Partridge T (2011) The status of exon skipping as a therapeutic approach to Duchenne muscular dystrophy. Mol Ther 19(1):9–15. doi:10.1038/mt.2010.219
Moulton JD, Jiang S (2009) Gene knockdowns in adult animals: PPMOs and vivo-morpholinos. Molecules 14(3):1304–1323. doi:10.3390/molecules14031304
Sazani P, Ness KP, Weller DL, Poage D, Nelson K, Shrewsbury AS (2011) Chemical and mechanistic toxicology evaluation of exon skipping phosphorodiamidate morpholino oligomers in mdx mice. Int J Toxicol 30(3):322–333. doi:10.1177/1091581811403504
Cirak S, Arechavala-Gomeza V, Guglieri M, Feng L, Torelli S, Anthony K, Abbs S, Garralda ME, Bourke J, Wells DJ, Dickson G, Wood MJ, Wilton SD, Straub V, Kole R, Shrewsbury SB, Sewry C, Morgan JE, Bushby K, Muntoni F (2011) Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378(9791):595–605. doi:10.1016/S0140-6736(11)60756-3
Heemskerk H, de Winter C, van Kuik P, Heuvelmans N, Sabatelli P, Rimessi P, Braghetta P, van Ommen GJ, de Kimpe S, Ferlini A, Aartsma-Rus A, van Deutekom JC (2010) Preclinical PK and PD studies on 2′-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model. Mol Ther 18(6):1210–1217. doi:10.1038/mt.2010.72
Goemans NM, Tulinius M, van den Akker JT, Burm BE, Ekhart PF, Heuvelmans N, Holling T, Janson AA, Platenburg GJ, Sipkens JA, Sitsen JM, Aartsma-Rus A, van Ommen GJ, Buyse G, Darin N, Verschuuren JJ, Campion GV, de Kimpe SJ, van Deutekom JC (2011) Systemic administration of PRO051 in Duchenne’s muscular dystrophy. N Engl J Med 364(16):1513–1522. doi:10.1056/NEJMoa1011367
Aoki Y, Yokota T, Nagata T, Nakamura A, Tanihata J, Saito T, Duguez SM, Nagaraju K, Hoffman EP, Partridge T, Takeda S (2012) Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. Proc Natl Acad Sci U S A 109(34):13763–13768. doi:10.1073/pnas.1204638109
Taniguchi-Ikeda M, Kobayashi K, Kanagawa M, Yu CC, Mori K, Oda T, Kuga A, Kurahashi H, Akman HO, DiMauro S, Kaji R, Yokota T, Takeda S, Toda T (2011) Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy. Nature 478(7367):127–131. doi:10.1038/nature10456
Yokota T, Nakamura A, Nagata T, Saito T, Kobayashi M, Aoki Y, Echigoya Y, Partridge T, Hoffman EP, Takeda S (2012) Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs. Nucleic Acid Ther 22(5):306–315. doi:10.1089/nat.2012.0368
Prakash TP, Bhat B (2007) 2′-Modified oligonucleotides for antisense therapeutics. Curr Top Med Chem 7(7):641–649
Altmann KH, Fabbro D, Dean NM, Geiger T, Monia BP, Muller M, Nicklin P (1996) Second-generation antisense oligonucleotides: structure-activity relationships and the design of improved signal-transduction inhibitors. Biochem Soc Trans 24(3):630–637
Monia BP, Lesnik EA, Gonzalez C, Lima WF, McGee D, Guinosso CJ, Kawasaki AM, Cook PD, Freier SM (1993) Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem 268(19):14514–14522
Hua Y, Sahashi K, Rigo F, Hung G, Horev G, Bennett CF, Krainer AR (2011) Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 478(7367):123–126. doi:10.1038/nature10485
Aartsma-Rus A, Bremmer-Bout M, Janson AA, den Dunnen JT, van Ommen GJ, van Deutekom JC (2002) Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Neuromuscul Disord 12(Suppl 1):S71–77
Echigoya Y, Yokota T (2014) Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides. Nucleic Acid Ther 24(1):57–68. doi:10.1089/nat.2013.0451
Yokota T, Duddy W, Echigoya Y, Kolski H (2012) Exon skipping for nonsense mutations in Duchenne muscular dystrophy: too many mutations, too few patients? Expert Opin Biol Ther 12(9):1141–1152. doi:10.1517/14712598.2012.693469
Aoki Y, Yokota T, Wood MJ (2013) Development of multiexon skipping antisense oligonucleotide therapy for Duchenne muscular dystrophy. Biomed Res Int 2013:402369. doi:10.1155/2013/402369
Yokota T, Duddy W, Partridge T (2007) Optimizing exon skipping therapies for DMD. Acta Myol 26(3):179–184
Pramono ZA, Takeshima Y, Alimsardjono H, Ishii A, Takeda S, Matsuo M (1996) Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynucleotide complementary to an exon recognition sequence. Biochem Biophys Res Commun 226(2):445–449
Mann CJ, Honeyman K, Cheng AJ, Ly T, Lloyd F, Fletcher S, Morgan JE, Partridge TA, Wilton SD (2001) Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci U S A 98(1):42–47
Lu QL, Rabinowitz A, Chen YC, Yokota T, Yin H, Alter J, Jadoon A, Bou-Gharios G, Partridge T (2005) Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci U S A 102(1):198–203
Yokota T, Lu QL, Partridge T, Kobayashi M, Nakamura A, Takeda S, Hoffman E (2009) Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol 65(6):667–676. doi:10.1002/ana.21627
Yokota T, Hoffman E, Takeda S (2011) Antisense oligo-mediated multiple exon skipping in a dog model of Duchenne muscular dystrophy. Methods Mol Biol 709:299–312. doi:10.1007/978-1-61737-982-6_20
McCarter GC, Steinhardt RA (2000) Increased activity of calcium leak channels caused by proteolysis near sarcolemmal ruptures. J Membr Biol 176(2):169–174
Kamoshita S, Konishi Y, Segawa M, Fukuyama Y (1976) Congenital muscular dystrophy as a disease of the central nervous system. Arch Neurol 33(7):513–516
Kobayashi K, Nakahori Y, Miyake M, Matsumura K, Kondo-Iida E, Nomura Y, Segawa M, Yoshioka M, Saito K, Osawa M, Hamano K, Sakakihara Y, Nonaka I, Nakagome Y, Kanazawa I, Nakamura Y, Tokunaga K, Toda T (1998) An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature 394(6691):388–392. doi:10.1038/28653
Hayashi YK, Ogawa M, Tagawa K, Noguchi S, Ishihara T, Nonaka I, Arahata K (2001) Selective deficiency of alpha-dystroglycan in Fukuyama-type congenital muscular dystrophy. Neurology 57(1):115–121
Michele DE, Barresi R, Kanagawa M, Saito F, Cohn RD, Satz JS, Dollar J, Nishino I, Kelley RI, Somer H, Straub V, Mathews KD, Moore SA, Campbell KP (2002) Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. Nature 418(6896):417–422. doi:10.1038/nature00837
Guglieri M, Bushby K (2008) How to go about diagnosing and managing the limb-girdle muscular dystrophies. Neurol India 56(3):271–280
Illa I, Serrano-Munuera C, Gallardo E, Lasa A, Rojas-Garcia R, Palmer J, Gallano P, Baiget M, Matsuda C, Brown RH (2001) Distal anterior compartment myopathy: a dysferlin mutation causing a new muscular dystrophy phenotype. Ann Neurol 49(1):130–134
Liu J, Aoki M, Illa I, Wu C, Fardeau M, Angelini C, Serrano C, Urtizberea JA, Hentati F, Hamida MB, Bohlega S, Culper EJ, Amato AA, Bossie K, Oeltjen J, Bejaoui K, McKenna-Yasek D, Hosler BA, Schurr E, Arahata K, de Jong PJ, Brown RH Jr (1998) Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet 20(1):31–36. doi:10.1038/1682
Matsuda C, Aoki M, Hayashi YK, Ho MF, Arahata K, Brown RH Jr (1999) Dysferlin is a surface membrane-associated protein that is absent in Miyoshi myopathy. Neurology 53(5):1119–1122
Argov Z, Sadeh M, Mazor K, Soffer D, Kahana E, Eisenberg I, Mitrani-Rosenbaum S, Richard I, Beckmann J, Keers S, Bashir R, Bushby K, Rosenmann H (2000) Muscular dystrophy due to dysferlin deficiency in Libyan Jews. Clinical and genetic features. Brain 123(Pt 6):1229–1237
Bansal D, Miyake K, Vogel SS, Groh S, Chen CC, Williamson R, McNeil PL, Campbell KP (2003) Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 423(6936):168–172
Anderson LV, Davison K, Moss JA, Young C, Cullen MJ, Walsh J, Johnson MA, Bashir R, Britton S, Keers S, Argov Z, Mahjneh I, Fougerousse F, Beckmann JS, Bushby KM (1999) Dysferlin is a plasma membrane protein and is expressed early in human development. Hum Mol Genet 8(5):855–861
Aoki M, Liu J, Richard I, Bashir R, Britton S, Keers SM, Oeltjen J, Brown HE, Marchand S, Bourg N, Beley C, McKenna-Yasek D, Arahata K, Bohlega S, Cupler E, Illa I, Majneh I, Barohn RJ, Urtizberea JA, Fardeau M, Amato A, Angelini C, Bushby K, Beckmann JS, Brown RH Jr (2001) Genomic organization of the dysferlin gene and novel mutations in Miyoshi myopathy. Neurology 57(2):271–278
Sinnreich M, Therrien C, Karpati G (2006) Lariat branch point mutation in the dysferlin gene with mild limb-girdle muscular dystrophy. Neurology 66(7):1114–1116. doi:10.1212/01.wnl.0000204358.89303.81
Wein N, Avril A, Bartoli M, Beley C, Chaouch S, Laforet P, Behin A, Butler-Browne G, Mouly V, Krahn M, Garcia L, Levy N (2010) Efficient bypass of mutations in dysferlin deficient patient cells by antisense-induced exon skipping. Hum Mutat 31(2):136–142. doi:10.1002/humu.21160
Krahn MWN, Nguyen K, Vial C, Courrier S, Lostal W, Bartoli M, Labelle V, Leturcq F, Cau P, Richard I, Levy N (2007) Functional evaluation of a putative mini-dysferlin identified in a patient with moderate Miyoshi myopathy phenotype. Neuromuscul Disord 17(9):790–790. doi:10.1016/j.nmd.2007.06.102
Aartsma-Rus A, Singh KH, Fokkema IF, Ginjaar IB, van Ommen GJ, den Dunnen JT, van der Maarel SM (2010) Therapeutic exon skipping for dysferlinopathies? Eur J Hum Genet 18(8):889–894. doi:10.1038/ejhg.2010.4
Harper P (2001) Myotonic dystrophy, 3rd edition: major problems in neurology series, No 37. W B Saunders, London
Harley HG, Brook JD, Rundle SA, Crow S, Reardon W, Buckler AJ, Harper PS, Housman DE, Shaw DJ (1992) Expansion of an unstable DNA region and phenotypic variation in myotonic dystrophy. Nature 355(6360):545–546. doi:10.1038/355545a0
Fugier C, Klein AF, Hammer C, Vassilopoulos S, Ivarsson Y, Toussaint A, Tosch V, Vignaud A, Ferry A, Messaddeq N, Kokunai Y, Tsuburaya R, de la Grange P, Dembele D, Francois V, Precigout G, Boulade-Ladame C, Hummel MC, Lopez de Munain A, Sergeant N, Laquerriere A, Thibault C, Deryckere F, Auboeuf D, Garcia L, Zimmermann P, Udd B, Schoser B, Takahashi MP, Nishino I, Bassez G, Laporte J, Furling D, Charlet-Berguerand N (2011) Misregulated alternative splicing of BIN1 is associated with T tubule alterations and muscle weakness in myotonic dystrophy. Nat Med 17(6):720–725. doi:10.1038/nm.2374
Koebis M, Ohsawa N, Kino Y, Sasagawa N, Nishino I, Ishiura S (2011) Alternative splicing of myomesin 1 gene is aberrantly regulated in myotonic dystrophy type 1. Genes Cells 16(9):961–972. doi:10.1111/j.1365-2443.2011.01542.x
Ohsawa N, Koebis M, Suo S, Nishino I, Ishiura S (2011) Alternative splicing of PDLIM3/ALP, for alpha-actinin-associated LIM protein 3, is aberrant in persons with myotonic dystrophy. Biochem Biophys Res Commun 409(1):64–69. doi:10.1016/j.bbrc.2011.04.106
Philips AV, Timchenko LT, Cooper TA (1998) Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science 280(5364):737–741
Ranum LP, Cooper TA (2006) RNA-mediated neuromuscular disorders. Annu Rev Neurosci 29:259–277. doi:10.1146/annurev.neuro.29.051605.113014
Savkur RS, Philips AV, Cooper TA (2001) Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet 29(1):40–47. doi:10.1038/ng704
Charlet BN, Savkur RS, Singh G, Philips AV, Grice EA, Cooper TA (2002) Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Mol Cell 10(1):45–53
Kanadia RN, Johnstone KA, Mankodi A, Lungu C, Thornton CA, Esson D, Timmers AM, Hauswirth WW, Swanson MS (2003) A muscleblind knockout model for myotonic dystrophy. Science 302(5652):1978–1980. doi:10.1126/science.1088583
Mankodi A, Takahashi MP, Jiang H, Beck CL, Bowers WJ, Moxley RT, Cannon SC, Thornton CA (2002) Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol Cell 10(1):35–44
Mulders SA, van den Broek WJ, Wheeler TM, Croes HJ, van Kuik-Romeijn P, de Kimpe SJ, Furling D, Platenburg GJ, Gourdon G, Thornton CA, Wieringa B, Wansink DG (2009) Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc Natl Acad Sci U S A 106(33):13915–13920. doi:10.1073/pnas.0905780106
Nakamori M, Gourdon G, Thornton CA (2011) Stabilization of expanded (CTG)*(CAG) repeats by antisense oligonucleotides. Mol Ther 19(12):2222–2227. doi:10.1038/mt.2011.191
Wheeler TM, Leger AJ, Pandey SK, MacLeod AR, Nakamori M, Cheng SH, Wentworth BM, Bennett CF, Thornton CA (2012) Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 488(7409):111–115. doi:10.1038/nature11362
Wheeler TM, Lueck JD, Swanson MS, Dirksen RT, Thornton CA (2007) Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J Clin Invest 117(12):3952–3957
Aartsma-Rus A, Fokkema I, Verschuuren J, Ginjaar I, van Deutekom J, van Ommen GJ, den Dunnen JT (2009) Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 30(3):293–299
Yokota T, Pistilli E, Duddy W, Nagaraju K (2007) Potential of oligonucleotide-mediated exon-skipping therapy for Duchenne muscular dystrophy. Expert Opin Biol Ther 7(6):831–842
Aartsma-Rus A, van Ommen GJ (2009) Less is more: therapeutic exon skipping for Duchenne muscular dystrophy. Lancet Neurol 8(10):873–875. doi:10.1016/S1474-4422(09)70229-7
Cirak S, Feng L, Anthony K, Arechavala-Gomeza V, Torelli S, Sewry C, Morgan JE, Muntoni F (2012) Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophy. Mol Ther 20(2):462–467. doi:10.1038/mt.2011.248
Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, Adkin C, Guglieri M, Ashton E, Abbs S, Nihoyannopoulos P, Garralda ME, Rutherford M, McCulley C, Popplewell L, Graham IR, Dickson G, Wood MJ, Wells DJ, Wilton SD, Kole R, Straub V, Bushby K, Sewry C, Morgan JE, Muntoni F (2009) Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 8(10):918–928
Muntoni F, Bushby K, van Ommen G (2005) 128th ENMC international workshop on ‘preclinical optimization and phase I/II clinical trials using antisense oligonucleotides in Duchenne muscular dystrophy’ 22–24 October 2004, Naarden, The Netherlands. Neuromuscul Disord 15(6):450–457
Acknowledgments
This work was supported by the University of Alberta Faculty of Medicine and Dentistry, Parent Project Muscular Dystrophy (USA), The Friends of Garrett Cumming Research Funds, HM Toupin Neurological Science Research Funds, Muscular Dystrophy Canada, Canada Foundation for Innovation, Alberta Enterprise and Advanced Education, Jesse’s Journey, Slipchuk SMA Research Funds, the Women and Children’s Health Research Institute, and Canadian Institutes of Health Research.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Japan
About this chapter
Cite this chapter
Lee, J.J.A., Yokota, T. (2016). Translational Research in Nucleic Acid Therapies for Muscular Dystrophies. In: Takeda, S., Miyagoe-Suzuki, Y., Mori-Yoshimura, M. (eds) Translational Research in Muscular Dystrophy. Springer, Tokyo. https://doi.org/10.1007/978-4-431-55678-7_6
Download citation
DOI: https://doi.org/10.1007/978-4-431-55678-7_6
Published:
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-55677-0
Online ISBN: 978-4-431-55678-7
eBook Packages: MedicineMedicine (R0)